Skip to content ↓

“Body on a chip” could improve drug evaluation

Human tissue samples linked by microfluidic channels replicate interactions of multiple organs.
Press Inquiries

Press Contact:

Sarah McDonnell
Phone: 617-253-8923
Fax: 617-258-8762
MIT News Office

Media Download

MIT engineers have designed a microfluidic platform that connects engineered tissue from up to 10 organs, allowing them to replicate human-organ interactions.
Download Image
Caption: MIT engineers have designed a microfluidic platform that connects engineered tissue from up to 10 organs, allowing them to replicate human-organ interactions.
Credits: Image: Felice Frankel
The new platform should allow researchers to measure the effects of experimental drugs on different parts of the body before testing them in humans.
Download Image
Caption: The new platform should allow researchers to measure the effects of experimental drugs on different parts of the body before testing them in humans.
Credits: Image: Felice Frankel

*Terms of Use:

Images for download on the MIT News office website are made available to non-commercial entities, press and the general public under a Creative Commons Attribution Non-Commercial No Derivatives license. You may not alter the images provided, other than to crop them to size. A credit line must be used when reproducing images; if one is not provided below, credit the images to "MIT."

Close
MIT engineers have designed a microfluidic platform that connects engineered tissue from up to 10 organs, allowing them to replicate human-organ interactions.
Caption:
MIT engineers have designed a microfluidic platform that connects engineered tissue from up to 10 organs, allowing them to replicate human-organ interactions.
Credits:
Image: Felice Frankel
The new platform should allow researchers to measure the effects of experimental drugs on different parts of the body before testing them in humans.
Caption:
The new platform should allow researchers to measure the effects of experimental drugs on different parts of the body before testing them in humans.
Credits:
Image: Felice Frankel

MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time, allowing them to measure the effects of drugs on different parts of the body.

Such a system could reveal, for example, whether a drug that is intended to treat one organ will have adverse effects on another.

“Some of these effects are really hard to predict from animal models because the situations that lead to them are idiosyncratic,” says Linda Griffith, the School of Engineering Professor of Teaching Innovation, a professor of biological engineering and mechanical engineering, and one of the senior authors of the study. “With our chip, you can distribute a drug and then look for the effects on other tissues, and measure the exposure and how it is metabolized.”

These chips could also be used to evaluate antibody drugs and other immunotherapies, which are difficult to test thoroughly in animals because they are designed to interact with the human immune system.

David Trumper, an MIT professor of mechanical engineering, and Murat Cirit, a research scientist in the Department of Biological Engineering, are also senior authors of the paper, which appears in the journal Scientific Reports. The paper’s lead authors are former MIT postdocs Collin Edington and Wen Li Kelly Chen.

Modeling organs

When developing a new drug, researchers identify drug targets based on what they know about the biology of the disease, and then create compounds that affect those targets. Preclinical testing in animals can offer information about a drug’s safety and effectiveness before human testing begins, but those tests may not reveal potential side effects, Griffith says. Furthermore, drugs that work in animals often fail in human trials.

“Animals do not represent people in all the facets that you need to develop drugs and understand disease,” Griffith says. “That is becoming more and more apparent as we look across all kinds of drugs.”

Complications can also arise due to variability among individual patients, including their genetic background, environmental influences, lifestyles, and other drugs they may be taking. “A lot of the time you don’t see problems with a drug, particularly something that might be widely prescribed, until it goes on the market,” Griffith says.

As part of a project spearheaded by the Defense Advanced Research Projects Agency (DARPA), Griffith and her colleagues decided to pursue a technology that they call a “physiome on a chip,” which they believe could offer a way to model potential drug effects more accurately and rapidly. To achieve this, the researchers needed new equipment — a platform that would allow tissues to grow and interact with each other — as well as engineered tissue that would accurately mimic the functions of human organs.

Before this project was launched, no one had succeeded in connecting more than a few different tissue types on a platform. Furthermore, most researchers working on this kind of chip were working with closed microfluidic systems, which allow fluid to flow in and out but do not offer an easy way to manipulate what is happening inside the chip. These systems also require external pumps.

The MIT team decided to create an open system, which essentially removes the lid and makes it easier to manipulate the system and remove samples for analysis. Their system, adapted from technology they previously developed and commercialized through U.K.-based CN BioInnovations, also incorporates several on-board pumps that can control the flow of liquid between the “organs,” replicating the circulation of blood, immune cells, and proteins through the human body. The pumps also allow larger engineered tissues, for example tumors within an organ, to be evaluated.

Complex interactions

The researchers created several versions of their chip, linking up to 10 organ types: liver, lung, gut, endometrium, brain, heart, pancreas, kidney, skin, and skeletal muscle. Each “organ” consists of clusters of 1 million to 2 million cells. These tissues don’t replicate the entire organ, but they do perform many of its important functions. Significantly, most of the tissues come directly from patient samples rather than from cell lines that have been developed for lab use. These so-called “primary cells” are more difficult to work with but offer a more representative model of organ function, Griffith says.

Using this system, the researchers showed that they could deliver a drug to the gastrointestinal tissue, mimicking oral ingestion of a drug, and then observe as the drug was transported to other tissues and metabolized. They could measure where the drugs went, the effects of the drugs on different tissues, and how the drugs were broken down. In a related publication, the researchers modeled how drugs can cause unexpected stress on the liver by making the gastrointestinal tract “leaky,” allowing bacteria to enter the bloodstream and produce inflammation in the liver.

Kevin Healy, a professor of bioengineering and materials science and engineering at the University of California at Berkeley, says that this kind of system holds great potential for accurate prediction of complex adverse drug reactions.

“While microphysiological systems (MPS) featuring single organs can be of great use for both pharmaceutical testing and basic organ-level studies, the huge potential of MPS technology is revealed by connecting multiple organ chips in an integrated system for in vitro pharmacology. This study beautifully illustrates that multi-MPS “physiome-on-a-chip” approaches, which combine the genetic background of human cells with physiologically relevant tissue-to-media volumes, allow accurate prediction of drug pharmacokinetics and drug absorption, distribution, metabolism, and excretion,” says Healy, who was not involved in the research.

Griffith believes that the most immediate applications for this technology involve modeling two to four organs. Her lab is now developing a model system for Parkinson’s disease that includes brain, liver, and gastrointestinal tissue, which she plans to use to investigate the hypothesis that bacteria found in the gut can influence the development of Parkinson’s disease.

Other applications include modeling tumors that metastasize to other parts of the body, she says.

“An advantage of our platform is that we can scale it up or down and accommodate a lot of different configurations,” Griffith says. “I think the field is going to go through a transition where we start to get more information out of a three-organ or four-organ system, and it will start to become cost-competitive because the information you’re getting is so much more valuable.”

The research was funded by the U.S. Army Research Office and DARPA.

Press Mentions

PBS NewsHour

Prof. Linda Griffith speaks with Hari Sreenivasan of PBS NewsHour about her work developing a new “body on a chip” that could allow researchers to test new drugs on organ tissue. Griffith explains that the device models how different organs and cells communicate in the human body, which is “really important for things like arthritis, Alzheimer's, where you've got multiple organs involved.”

The Wall Street Journal

Prof. Linda Griffith speaks with Wall Street Journal reporter Mark Ellwood about her work developing a new device that allows researchers to test how a drug affects the human body. Ellwood notes that the technology that Griffith and her team have created “could prove vital for rapidly releasing new vaccines.”

New Scientist

Prof. Linda Griffith has developed ten miniature models of human organs “to create the closest we’ve come yet to a human-on-a-chip,” writes Jessica Hamzelou for New Scientist. “This is still only a minimal representation of a human,” said Griffith, but this kind of system could eventually eliminate the need for animal testing.

TechCrunch

Prof. Linda Griffith has created a “complex platform where researchers can put up to 10 organ tissues in separate compartments, regulating the flow of substances and medications between them in real time,” to determine how each organ will react, writes Devin Coldewey for TechCrunch.  The scale of this model “represents a huge jump in the capabilities of this kind of system.”

Related Links

Related Topics

Related Articles

More MIT News

Photo of Annauk Olin with her husband and baby

Saving Iñupiaq

Linguistics graduate student Annauk Olin is helping her Alaska Native community preserve their language and navigate the severe impact of climate change.

Read full story